Belcopa
A practitioner-mediated behavioral intervention studying informed expectation, therapeutic context, ritual, and symptom interpretation.
Concept
Ethics
Pilot
Controlled
Validate
Scale
Clinical-stage ambition · research-stage evidence
New beginnings
require new evidence.
trūth is developing two investigational therapeutic concepts for multiple-sclerosis symptomology through disciplined clinical planning, transparent evidence, and patient-centered design.
Lead programs
Two concepts. Two development paths.
Belcopa is a practitioner-mediated behavioral intervention. NovusClarus is a proposed fixed-dose pharmaceutical product. They share an evidence standard, not a regulatory pathway.
NovusClarus
A proposed once-weekly fixed-dose capsule containing 50 mg MDMA and 500 mg acetaminophen for MS symptomology, requiring controlled component analysis.
Dossier
Formulation
Pre-IND
Phase 1
Phase 2
Review
Evidence architecture
Every claim carries its provenance.
The public site distinguishes external evidence, case observation, proposed mechanism, unresolved question, planned endpoint, and regulatory status.
External Evidence
Published literature and regulatory sources.
Case Observation
Documented single-subject findings and reports.
Proposed Mechanism
Testable biological or behavioral rationale.
Open Question
Unresolved uncertainty requiring study.
Planned Endpoint
Prospective measures for future trials.
Featured research
A case signal, not a product conclusion.
The foundational manuscript documents a single-subject low-dose MDMA case alongside Kesimpta and acupuncture. It does not directly test the proposed NovusClarus fixed-dose combination product.
Case observationWorking manuscriptNot peer reviewed
Working manuscript
Low-Dose MDMA & MS Symptomology
Medical anthropological case study by Sean Roberts, Patrick Mooney, Leticia Castro.
View Evidence RecordPartnership
The next milestone is institutional.
trūth is seeking scientific, clinical, regulatory, manufacturing, ethics, biostatistics, and advisory partners prepared to challenge the hypotheses.
Scientific & Clinical
Neurology, MS research, pain medicine, clinical investigation, psychedelic science, and medical anthropology.
Regulatory & Development
Pre-IND strategy, controlled-substance research, CMC, toxicology, trial operations, and safety monitoring.
Advisory Board
Independent experts able to question assumptions, protect participants, and improve study design.
Clinical-stage ambition · research-stage evidence
New beginnings
require new evidence.
Two investigational therapeutic concepts for MS symptomology, developed through transparent evidence and disciplined clinical planning.
Lead programs
Two concepts. Two
paths.
Belcopa
Practitioner-mediated behavioral intervention studying informed expectation, context, ritual, and symptom interpretation.
NovusClarus
Proposed once-weekly 50 mg MDMA / 500 mg acetaminophen fixed-dose capsule requiring randomized component analysis.
Evidence
Every claim carries its provenance.
The foundational manuscript is unfinished, unpublished, and not peer reviewed. It does not directly test the fixed-dose product.
Featured research
Read the manuscript in page.
Working manuscriptLow-Dose MDMA & MS Symptomology
Single-subject medical anthropological case study.